Barclays
RAPP

Barclays’s Rapport Therapeutics RAPP Stock Holding History

Barclays’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$301K Sell
9,611
-42,869
-82% -$1.21M ﹤0.01% 3471
2025
Q4 		$1.59M Buy
52,480
+25,767
+96% +$713K ﹤0.01% 3095
2025
Q3 		$793K Sell
26,713
-44,395
-62% -$792K ﹤0.01% 3514
2025
Q2 		$808K Buy
71,108
+8,412
+13% +$89.3K ﹤0.01% 3477
2025
Q1 		$629K Buy
62,696
+44,199
+239% +$574K ﹤0.01% 3383
2024
Q4 		$328K Buy
18,497
+5,634
+44% +$125K ﹤0.01% 4068
2024
Q3 		$263K Buy
12,863
+3,463
+37% +$74.4K ﹤0.01% 4151
2024
Q2 		$219K Buy
+9,400
New +$218K ﹤0.01% 3531

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Barclays's RAPP Position: Q1 2026 in Review

Barclays reduced its Rapport Therapeutics (RAPP) stake by 82% in Q1 2026, selling an estimated $1.21M and leaving 9,611 shares worth $301K. The position accounts for ﹤0.01% of the portfolio, ranked #3471.

Barclays first reported a position in RAPP in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.59M in Q4 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Barclays held 9,611 shares of Rapport Therapeutics worth $301K as of Q1 2026.
  • Barclays sold 42,869 Rapport Therapeutics shares in Q1 2026, an estimated $1.21M.
  • Rapport Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3471 holding.
  • Barclays first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Barclays's Rapport Therapeutics position peaked at $1.59M in Q4 2025.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.